What is the equity of RegeneRx Biopharmaceuticals this year?
RegeneRx Biopharmaceuticals has equity of -3.45 M USD this year.
In 2024, RegeneRx Biopharmaceuticals's equity was -3.45 M USD, a 54.51% increase from the -2.23 M USD equity in the previous year.
RegeneRx Biopharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding RegeneRx Biopharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating RegeneRx Biopharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
RegeneRx Biopharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in RegeneRx Biopharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
RegeneRx Biopharmaceuticals has equity of -3.45 M USD this year.
The equity of RegeneRx Biopharmaceuticals has increased/decreased by 54.51% increased compared to the previous year.
A high equity is advantageous for investors of RegeneRx Biopharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of RegeneRx Biopharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of RegeneRx Biopharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of RegeneRx Biopharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of RegeneRx Biopharmaceuticals include profits, dividend payments, capital increases, and acquisitions.
The equity of RegeneRx Biopharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, RegeneRx Biopharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, RegeneRx Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RegeneRx Biopharmaceuticals is expected to pay a dividend of 0 USD.
The current dividend yield of RegeneRx Biopharmaceuticals is .
RegeneRx Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .
RegeneRx Biopharmaceuticals paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
RegeneRx Biopharmaceuticals is assigned to the 'Health' sector.
To receive the latest dividend of RegeneRx Biopharmaceuticals from 10/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.
The last dividend was paid out on 10/7/2024.
In the year 2023, RegeneRx Biopharmaceuticals distributed 0 USD as dividends.
The dividends of RegeneRx Biopharmaceuticals are distributed in USD.
Our stock analysis for RegeneRx Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RegeneRx Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.